Takeda Presents Phase 2 Data on Maintenance with Single-Agent Investigational Ixazomib in Patients with Newly Diagnosed Multiple Myeloma
SAN FRANCISCO, Dec. 9, 2014 /PRNewswire/ -- Takeda Pharmaceutical Company Limited (TSE:4502) today announced results from an open-label, Phase 2 study evaluating the safety and efficacy of oral, single-agent ixazomib (MLN9708) as maintenance therapy in patients with multiple myeloma (MM) who had ...
Seattle Genetics and Takeda Report Phase 3 AETHERA Clinical Trial Data from ADCETRIS(R) (Brentuximab Vedotin) in Post-Transplant Hodgkin Lymphoma Patients at Risk of Relapse at ASH Annual Meeting
SAN FRANCISCO, Dec. 9, 2014 /PRNewswire/ -- Seattle Genetics, Inc.
Seattle Genetics and Takeda Announce Four-Year Survival Data from ADCETRIS® (Brentuximab Vedotin) Pivotal Trial in Relapsed or Refractory Systemic Anaplastic Large Cell Lymphoma at ASH Annual Meeting
SAN FRANCISCO, Dec. 9, 2014 /PRNewswire/ -- Seattle Genetics, Inc.
Takeda's Investigational, Oral Proteasome Inhibitor Ixazomib Granted Breakthrough Therapy Designation by U.S. FDA for Relapsed or Refractory Systemic Light-chain Amyloidosis
SINGAPORE, Dec. 5, 2014 /PRNewswire/ -- Takeda Pharmaceutical Company Limited (TSE: 4502) today announced that the U.S. Food & Drug Administration (FDA) has granted Breakthrough Therapy status to the company's investigational, oral proteasome inhibitor, ixazomib (MLN9708), for the treatment of re...
